Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2022-02-22 15:01:16 UTC |
---|
NP-MRD ID | NP0000925 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Niacinamide |
---|
Description | Niacinamide, also known as nicotinamide (NAM), is a form of vitamin B3 found in food and used as a dietary supplement and medication. Niacinamide belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. The structure of nicotinamide consists of a pyridine ring to which a primary amide group is attached in the meta position. It is an amide of nicotinic acid. As an aromatic compound, it undergoes electrophilic substitution reactions and transformations of its two functional groups. Niacinamide and phosphoribosyl pyrophosphate can be converted into nicotinic acid mononucleotide and phosphate by the enzyme nicotinamide phosphoribosyltransferase. In humans, niacinamide is involved in the metabolic disorder called the nad+ signalling pathway (cancer). Niacinamide is an odorless tasting compound. Outside of the human body, niacinamide is found, on average, in the highest concentration within a few different foods, such as common sages, cow milk, and cocoa beans and in a lower concentration in common pea. Niacinamide has also been detected, but not quantified in several different foods, such as yardlong beans, roselles, apples, oyster mushrooms, and swiss chards. Niacinamide occurs in trace amounts mainly in meat, fish, nuts, and mushrooms, as well as to a lesser extent in some vegetables. It is commonly added to cereals and other foods. Many multivitamins contain 20–30 mg of vitamin B3 and it is also available in higher doses. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. |
---|
Structure | InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) |
---|
Synonyms | Value | Source |
---|
3-Carbamoylpyridine | ChEBI | 3-Pyridinecarboxamide | ChEBI | beta-Pyridinecarboxamide | ChEBI | m-(Aminocarbonyl)pyridine | ChEBI | Niacin | ChEBI | Niamide | ChEBI | Nicotinamid | ChEBI | Nicotinamida | ChEBI | Nicotinamidum | ChEBI | Nicotine acid amide | ChEBI | Nicotine amide | ChEBI | Nicotinic acid amide | ChEBI | Nicotinic amide | ChEBI | Nicotinsaeureamid | ChEBI | Nicotylamide | ChEBI | Nikotinamid | ChEBI | Nikotinsaeureamid | ChEBI | Pyridine-3-carboxylic acid amide | ChEBI | Vitamin b3 | ChEBI | Vitamin PP | ChEBI | Nicotinamide | Kegg | b-Pyridinecarboxamide | Generator | Β-pyridinecarboxamide | Generator | Nicotinate amide | Generator | Pyridine-3-carboxylate amide | Generator | 3-Pyridinecarboxylic acid amide | HMDB | Acid amide | HMDB | Amid kyseliny nikotinove | HMDB | Amide PP | HMDB | Aminicotin | HMDB | Amixicotyn | HMDB | Amnicotin | HMDB | Austrovit PP | HMDB | Benicot | HMDB | Delonin amide | HMDB | Dipegyl | HMDB | Dipigyl | HMDB | Endobion | HMDB | Factor PP | HMDB | Hansamid | HMDB | Inovitan PP | HMDB | Mediatric | HMDB | NAM | HMDB | Nandervit-N | HMDB | Niacevit | HMDB | Niavit PP | HMDB | Nicamide | HMDB | Nicamina | HMDB | Nicamindon | HMDB | Nicasir | HMDB | Nicobion | HMDB | Nicofort | HMDB | Nicogen | HMDB | Nicomidol | HMDB | Nicosan 2 | HMDB | Nicosylamide | HMDB | Nicota | HMDB | Nicotamide | HMDB | Nicotilamide | HMDB | Nicotililamido | HMDB | Nicotinsaureamid | HMDB | Nicotol | HMDB | Nicotylamidum | HMDB | Nicovel | HMDB | Nicovit | HMDB | Nicovitina | HMDB | Nicovitol | HMDB | Nicozymin | HMDB | Nictoamide | HMDB | Niko-tamin | HMDB | Niocinamide | HMDB | Niozymin | HMDB | Papulex | HMDB | Pelmin | HMDB | Pelmine | HMDB | Pelonin amide | HMDB | PP-Faktor | HMDB | Propamine a | HMDB | Savacotyl | HMDB | Vi-nicotyl | HMDB | Vi-noctyl | HMDB | Witamina PP | HMDB | 3 Pyridinecarboxamide | HMDB | Astra brand OF niacinamide | HMDB | b 3, Vitamin | HMDB | Niacinamide merck brand | HMDB | Pharmagenix brand OF niacinamide | HMDB | b3, Vitamin | HMDB | Enduramide | HMDB | Jenapharm, nicotinsäureamid | HMDB | Niacinamide jenapharm brand | HMDB | Niacinamide pharmagenix brand | HMDB | Jenapharm brand OF niacinamide | HMDB | Nicotinsäureamid jenapharm | HMDB | Vitamin b 3 | HMDB | Merck brand OF niacinamide | HMDB | Niacinamide astra brand | HMDB | Niacinamide | ChEBI |
|
---|
Chemical Formula | C6H6N2O |
---|
Average Mass | 122.1246 Da |
---|
Monoisotopic Mass | 122.04801 Da |
---|
IUPAC Name | pyridine-3-carboxamide |
---|
Traditional Name | nicotinamide |
---|
CAS Registry Number | 98-92-0 |
---|
SMILES | NC(=O)C1=CC=CN=C1 |
---|
InChI Identifier | InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) |
---|
InChI Key | DFPAKSUCGFBDDF-UHFFFAOYSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, simulated) | Ahselim | | | 2022-02-22 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 400 MHz, H2O, simulated) | v.dorna83@yahoo.com | Not Available | Not Available | 2021-08-03 | View Spectrum |
| Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Pyridinecarboxylic acids and derivatives |
---|
Direct Parent | Nicotinamides |
---|
Alternative Parents | |
---|
Substituents | - Nicotinamide
- Heteroaromatic compound
- Primary carboxylic acid amide
- Carboxamide group
- Azacycle
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 130 °C | Not Available | Boiling Point | 334.41 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | Water Solubility | 500 mg/mL at 25 °C | Not Available | LogP | -0.37 | Hansch CH, Leo A and Hoekman DH. "Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. Volume 1" ACS Publications (1995). |
|
---|
Predicted Properties | |
---|
General References | - Draelos ZD, Ertel K, Berge C: Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005 Aug;76(2):135-41. [PubMed:16209160 ]
- Soma Y, Kashima M, Imaizumi A, Takahama H, Kawakami T, Mizoguchi M: Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005 Mar;44(3):197-202. [PubMed:15807725 ]
- Authors unspecified: Final report of the safety assessment of niacinamide and niacin. Int J Toxicol. 2005;24 Suppl 5:1-31. [PubMed:16596767 ]
- Draelos ZD, Matsubara A, Smiles K: The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006 Jun;8(2):96-101. [PubMed:16766489 ]
- Yang L, Yao Y, Shi Y, Wang X, Shi J: [Expression of nicotinamide edenine dinucleotide dehydrogenase gene in placenta of patients with pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi. 2002 Nov;37(11):660-2. [PubMed:12487919 ]
- Sonee M, Martens JR, Mukherjee SK: Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary butylhydroperoxide (t-BuOOH). Neurotox Res. 2002 Nov-Dec;4(7-8):595-599. [PubMed:12709297 ]
- Sonee M, Martens JR, Evers MR, Mukherjee SK: The effect of tertiary butylhydroperoxide and nicotinamide on human cortical neurons. Neurotoxicology. 2003 Jun;24(3):443-8. [PubMed:12782109 ]
- Anisimov AG, Bolotnikov IA: [Nicotinamide decreases DNA destabilization in K562 cells treated with AlF(-4)]. Tsitologiia. 1997;39(9):822-8. [PubMed:9518388 ]
- Matuoka K, Chen KY, Takenawa T: Rapid reversion of aging phenotypes by nicotinamide through possible modulation of histone acetylation. Cell Mol Life Sci. 2001 Dec;58(14):2108-16. [PubMed:11814060 ]
- Bartalena L, Tanda ML, Piantanida E, Lai A: Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors. 2003;19(3-4):155-63. [PubMed:14757966 ]
- Bissett DL, Oblong JE, Berge CA: Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005 Jul;31(7 Pt 2):860-5; discussion 865. [PubMed:16029679 ]
- Baeza N, Moriscot C, Figarella C, Guy-Crotte O, Vialettes B: Reg protein: a potential beta-cell-specific growth factor? Diabetes Metab. 1996 Jul;22(4):229-34. [PubMed:8767167 ]
- Hoskin PJ, Rojas AM, Phillips H, Saunders MI: Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer. 2005 Jun 1;103(11):2287-97. [PubMed:15834926 ]
- Rembold CM: Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. Curr Diab Rep. 2004 Oct;4(5):330-4. [PubMed:15461896 ]
- Kawasaki E, Abiru N, Eguchi K: Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S27-32. [PubMed:15563975 ]
- Linani A, Benarous K, Bou-Salah L, Yousfi M, Goumri-Said S: Exploring Structural Mechanism of COVID-19 Treatment with Glutathione as a Potential Peptide Inhibitor to the Main Protease: Molecular Dynamics Simulation and MM/PBSA Free Energy Calculations Study. Int J Pept Res Ther. 2022;28(2):55. doi: 10.1007/s10989-022-10365-6. Epub 2022 Jan 21. [PubMed:35079241 ]
|
---|